Impact of intraoperative goal-directed fluid therapy on major morbidity and mortality after transthoracic oesophagectomy: a multicentre, randomised controlled trial

Transthoracic oesophagectomy is associated with major morbidity and mortality, which may be reduced by goal-directed therapy (GDT). The aim of this multicentre, RCT was to evaluate the impact of intraoperative GDT on major morbidity and mortality in patients undergoing transthoracic oesophagectomy....

Full description

Saved in:
Bibliographic Details
Published inBritish journal of anaesthesia : BJA Vol. 125; no. 6; pp. 953 - 961
Main Authors Mukai, Akira, Suehiro, Koichi, Watanabe, Ryota, Juri, Takashi, Hayashi, Yasue, Tanaka, Katsuaki, Fujii, Takashi, Ohira, Naoko, Oda, Yutaka, Okutani, Ryu, Nishikawa, Kiyonobu
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.12.2020
Subjects
Online AccessGet full text
ISSN0007-0912
1471-6771
1471-6771
DOI10.1016/j.bja.2020.08.060

Cover

More Information
Summary:Transthoracic oesophagectomy is associated with major morbidity and mortality, which may be reduced by goal-directed therapy (GDT). The aim of this multicentre, RCT was to evaluate the impact of intraoperative GDT on major morbidity and mortality in patients undergoing transthoracic oesophagectomy. Adult patients undergoing transthoracic oesophagectomy were randomised to receive either minimally invasive intraoperative GDT (stroke volume variation <8%, plus systolic BP maintained >90 mm Hg by pressors as necessary) or haemodynamic management left to the discretion of attending senior anaesthetists (control group; systolic BP >90 mm Hg alone). The primary outcome was the incidence of death or major complications (reoperation for bleeding, anastomotic leakage, pneumonia, reintubation, >48 h ventilation). A Cox proportional hazard model was used to examine whether the effects of GDT on morbidity and mortality were independent of other potential confounders. A total of 232 patients (80.6% male; age range: 36–83 yr) were randomised to either GDT (n=115) or to the control group (n=117). After surgery, major morbidity and mortality were less frequent in 22/115 (19.1%) subjects randomised to GDT, compared with 41/117 (35.0%) subjects assigned to the control group {absolute risk reduction: 15.9% (95% confidence interval [CI]: 4.7–27.2%); P=0.006}. GDT was also associated with fewer episodes of atrial fibrillation (odds ratio [OR]: 0.18 [95% CI: 0.05–0.65]), respiratory failure (OR: 0.27 [95% CI: 0.09–0.83]), use of mini-tracheotomy (OR: 0.29 [95% CI: 0.10–0.81]), and readmission to ICU (OR: 0.09 [95% CI: 0.01–0.67]). GDT was independently associated with morbidity and mortality (hazard ratio: 0.51 [95% CI: 0.30–0.87]; P=0.013). Intraoperative GDT may reduce major morbidity and mortality, and shorten hospital stay, after transthoracic oesophagectomy. UMIN000018705
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0007-0912
1471-6771
1471-6771
DOI:10.1016/j.bja.2020.08.060